Gland Pharma Q4 PAT jumps 97% in FY26; ₹20 dividend

What changed for Gland Pharma in Q4 FY26

Gland Pharma reported a strong March-quarter performance, supported by higher revenue, improved operating leverage, and a sharp jump in profitability. Consolidated net profit for Q4 FY26 rose 96.62% year-on-year to ₹366.7 crore. Revenue from operations increased 22.31% to ₹1,742.8 crore compared with the year-ago quarter. The company also disclosed that its quarterly performance came despite a one-time exceptional charge linked to labour code implementation. The results were part of its audited financials for Q4 FY26 and the full year ended March 31, 2026.

Stock reaction: early spike, weaker close

Following the results, the stock was reported to have surged 12.37% to ₹2,098.05. However, the same day also saw the shares end lower, with the stock closing down 1.80% at ₹1,861 on the BSE. Such a move suggests a volatile session around earnings, where early optimism can meet profit-taking or reassessment as investors digest details. The article does not provide intraday timelines, but it clearly reflects both the sharp post-result jump and the closing decline. Investors typically track whether margin gains are sustainable and how much of the quarter’s lift is driven by mix, pricing, or operating leverage.

Q4 FY26 headline numbers: profit growth outpaces revenue

Gland Pharma’s Q4 FY26 net profit rose to ₹366.7 crore on revenue from operations of ₹1,742.8 crore. Profit before tax (PBT) increased 75.42% to ₹505.79 crore from ₹288.33 crore in Q4 FY25. Consolidated EBITDA stood at ₹513 crore, up 48% year-on-year, with an EBITDA margin of 29%. Separately, the company reported adjusted Q4 PAT of ₹366.7 crore (97% rise) and also presented PAT margin at 21% for the quarter. These numbers indicate that profitability expanded faster than sales, implying improved cost structure and/or better business mix during the period.

Sequential trend: steady revenue, stronger bottom line

The company reported sequential revenue growth of 2.8% over ₹1,695 crore in Q3 FY26. Total income for Q4 FY26 stood at ₹1,854 crore versus ₹1,469 crore in Q4 FY25 and ₹1,759 crore in Q3 FY26. Profit before exceptional item and tax rose to ₹506 crore from ₹288 crore in the year-ago quarter and ₹386 crore in the preceding quarter. While the article does not quantify the exceptional charge, it flags that the quarter included a one-time item related to labour code implementation. Taken together, the data points show a modest quarter-on-quarter revenue lift but a much stronger expansion in profit and pre-tax earnings.

Geography: US and Europe led the revenue rise

The company’s Q4 FY26 regional performance showed strength across major markets, with a few pockets of softness. Revenue from the US aggregated to ₹980.7 crore, up 25.44% year-on-year. Europe contributed ₹381.4 crore, up 36% year-on-year. Revenue from the rest of the world was ₹254.9 crore, up 6% year-on-year. Sales in Canada, Australia and New Zealand were ₹58.8 crore, down 2% year-on-year, while India sales were ₹67 crore, up 28% year-on-year.

CDMO contribution and margin commentary

The company highlighted that its CDMO business grew 36% year-on-year and contributed 46% of consolidated revenues in Q4 FY26. This is important because CDMO revenue can influence margins depending on product mix and execution. Executive Chairman Srinivas Sadu said the strong FY26 performance, including 14.5% consolidated revenue growth and an adjusted EBITDA margin of 26%, reflected progress across the businesses including Cenexi. He also noted that the 38% adjusted EBITDA margin of the base business was supported by robust CDMO growth, new product launches, and improved profitability across the existing portfolio, aided by cost-efficiency initiatives.

Full-year FY26: record revenue and higher adjusted PAT

For the full year, Gland Pharma reported consolidated revenue of ₹6,430.7 crore, up 14.5%. Full-year adjusted PAT rose 50% to ₹1,045.5 crore. The company described FY26 as a year of record consolidated revenues and profitability. While the article provides multiple profitability metrics (including adjusted numbers), the key takeaway is that earnings growth outpaced top-line growth at the full-year level as well.

Dividend: ₹20 per share, AGM and record date

The Board recommended a final dividend of ₹20 per equity share (face value ₹1 each), described as 2000%, for FY26. The dividend is subject to shareholder approval at the 48th Annual General Meeting scheduled for Tuesday, August 25, 2026. The record date for the dividend was reported as August 11, 2026. Dividend announcements matter for income-focused investors, but approval and timelines are also key, especially for investors tracking eligibility based on settlement cycles.

Market impact and what investors may track next

The quarter’s numbers show a sharp improvement in profitability, with PAT up nearly 97% and EBITDA margins reported at 29% for Q4 FY26. Geographic performance indicates that the US and Europe remained key drivers, while India grew off a smaller base and Canada-Australia-New Zealand saw a slight decline. Management’s focus on CDMO growth and cost-efficiency initiatives provides context for the margin expansion reported in the quarter. The next milestones mentioned are the record date (August 11, 2026) and shareholder approval at the AGM (August 25, 2026). Investors are likely to keep monitoring the sustainability of margins, the CDMO revenue share, and any further disclosures around exceptional charges linked to labour code implementation.